AGP Executive Report
Last update: 10 hours agoUS Pharma Tariff Relief: The US Commerce Department has published a Federal Register list granting 0% ad valorem tariffs on select speciality medicines and related ingredients from India and 19 other jurisdictions, even as a broader 100% tariff on certain patented pharma lines is set to start Sept 29. What’s Covered: The zero-duty categories include orphan drugs for rare diseases, fertility treatments, cell and gene therapies, antibody-drug conjugates (ADCs), certain medical countermeasures, and veterinary pharmaceuticals—plus key manufacturing components. Liechtenstein in the Mix: Liechtenstein is named among the eligible jurisdictions, alongside Switzerland and the EU. Healthcare Staffing Pressure: Separately, EU-area worker limits in Ireland’s healthcare sector are being temporarily relaxed to tackle severe staff shortages, with nursing homes and home-care services hit hardest. Rare Disease Treatment Update: The European Commission granted marketing authorization for NEZGLYAL® (leriglitazone) for early male cerebral adrenoleukodystrophy (cALD), with Germany expected to be the first launch market.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.